HibMenCY-TT + DTaP-HBV-IPV vaccinees were re-randomized ( @:@:@ ) to receive MenACWY-TT at @-@ months and DTaP at @-@ months ( MenACWY-TT group ) ; MenACWY-TT co-administered with DTaP at @-@ months ( Coad group ) ; or HibMenCY-TT at @-@ months and DTaP at @-@ months ( HibMenCY-TT group ) .